Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-03-28

Clinical Trial Update: AMG 334 20160172 Pediatric Migraine PK Study. [Phase 1]

View source ↗

Summary

The update reports the completion of a Phase 1 pediatric pharmacokinetic study of AMG 334 (erenumab) for migraine, with results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • AMG 334 (erenumab)

Snippet

Sponsor: Amgen | Conditions: Migraine | Phase 1 | Status: COMPLETED | Results posted: 2024-03-28